JPRN-UMIN000005408已完成未知
miriplatin-TAI in TACE refractory HCC - National Cancer Center Clinical Studies in HBPO group -002
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •Child-Pugh C
研究者
相似试验
已完成
不适用
Salvage TACE for unresectable HCC: switching the chemotherapeutic agents.JPRN-UMIN000015887Kanagawa Cancer Center200
已完成
不适用
TACE-HAIC Combined With TKIs and Immunotherapy Versus TACE Alone for Hepatocellular Carcinoma With PVTTHepatocellular CarcinomaNCT05535998Yunfei Yuan743
Unknown
2 期
TACE Combinated With Sorafenib in Treating Patients With Unresectable Hepatocellular CarcinomaPHENYTOIN/SORAFENIB [VA Drug Interaction]Carcinoma, HepatocellularNCT01605734Shandong Cancer Hospital and Institute120
已完成
4 期
Study to Collect more detailedinformation concerning TACE treatment followed by Sorafenib for hepatocellularcarcinoma (HCC) or without sorafenib after TACE enabling us to evaluate thetime to meet criteria for TACE non-eligibilityCTRI/2014/12/005310Bayer pharmaceuticals Pvt Ltd55
已完成
3 期
Chemoembolization With or Without Mixing the Chemotherapy With Lipiodol for Unresectable HCCHepatocellular CarcinomaNCT01229839Sun Yat-sen University668